New York, New York (PRWEB) September 28, 2011
Parker Waichman Alonso LLP urges the U.S. Food & Drug Administration (FDA) to continue its ongoing safety review of Yaz, Yasmin and other birth control pills containing the synthetic progestin, drospirenone, in light of preliminary results from an FDA-funded study which suggested that women who use these medications face a 1.5-fold increased risk of suffering a blood clot compared to women using other hormonal contraceptives. The study, which involves 800,000 women, is exploring the association between blood clots and several different hormonal contraceptive products.
In a Drug Safety Communication posted on its website on September 26, the FDA said it remained concerned “about the potential increased risk of blood clots with the use of drospirenone-containing birth control pills." Only two of the six completed studies reviewed by the FDA as part of its ongoing safety review did not find a higher risk of blood clots among women who used drospirenone-containing birth control pills. According to the FDA Drug Safety Communication, preliminary findings from the agency-funded study in regards to drospirenone “appear consistent with results” from two studies published in 2009 and two others published in 2011 that also suggested a higher risk of blood clots among women taking drospirenone birth contol pills compared to those using other oral contraceptives. Considering these findings, it is clear that the FDA must subject Yaz, Yasmin and similar oral contraceptives to further review in order to better understand their association with blood clots and other serious side effects.
Drospirenone is a synthetic form of progestin which can elevate the body's potassium levels, leading to a condition called hyperkalemia in certain patients. Hyperkalemia may result in potentially serious heart and health problems. Adverse Events reported to the FDA involving Yaz , Yasmin and similar medications include heart arrhythmias, electrolyte imbalance, hyponatremis, hyperkalemia, hyperkalemic arrhythmias, atrial fibrillation, tachycardia, bradycardia, myocardial infarction, stroke, transient ischemic attack, blood clots, embolisms, and sudden death.
In addition to Yaz and Yasmin, other oral contraceptives made with drospirenone include Beyaz, Gianvi, Loryna, Ocella, Safyral, Syeda, and Zarah.
More than 9,000 lawsuits have been filed against Bayer Corporation, the manufacturer of Yaz and Yasmin, as well as other makers of drospirenone-containing birth control pills by women who claim to have suffered strokes, pulmonary emboli, deep vein thrombosis, blood clots, gallbladder disease, and other serious injuries after taking these medications. Over 7,000 such lawsuits have been consolidated in the Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100) currently pending before the Honorable Judge David R. Herndon in the United States District Court for the Southern District of Illinois. Andres F. Alonso, Esq., a partner with Parker Waichman Alonso LLP, is serving as a member of the Plaintiffs Steering Committee in that litigation.
Parker Waichman Alonso LLP continues to offer free legal evaluations to victims of drospirenone contraceptives, including Yaz and Yasmin. If you or a loved one suffered a heart attack, blood clot or stroke while taking one of these birth control pills, please visit the firm's Yaz and Yasmin injury page at http://www.yourlawyer.com
For more information regarding Yaz and Yasmin lawsuits and Parker Waichman Alonso LLP, please visit: http://www.yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).
Contact: Parker Waichman Alonso LLP
Dave Krangle, Attorney